Percutaneous Coronary Intervention

Nearly 1 in 10 patients are readmitted to the hospital multiple times within 180 days post-PCI and nearly one-quarter of those with multiple readmissions return to the hospital for the same cause each time, according to research published in Catheterization and Cardiovascular Interventions.

The increasing use of transradial access for PCI over time did not compromise door-to-balloon times in patients with STEMI requiring PCI, according to new findings.

Among patients with ACS, periprocedural loading doses of atorvastatin before planned PCI did not reduce MACE at 12 months compared with placebo, according to new data from the SECURE-PCI trial.

Preprocedural colchicine for reduction of post-PCI adverse CV outcomes.

Healio and Cardiology Today compiled a list of the most-read cardiac and vascular intervention articles published in 2019.

Immediate vs. delayed coronary angiography in patients indicated for PCI.

Among patients who underwent PCI, those with cancer had elevated risks for cardiac mortality and bleeding, researchers reported in JACC: CardioOncology.

The European Association for Cardio-Thoracic Surgery has withdrawn its support for the left main disease recommendations of the 2018 European Association for Cardio-Thoracic Surgery/European Society of Cardiology Clinical Guidelines for Myocardial Revascularization, but a portion of the association’s explanation has drawn criticism from the Society for Cardiovascular Angiography and Interventions.

Invasive strategy vs. conservative strategy for treatment of patients with moderate or severe ischemia.

PHILADELPHIA — Acute preprocedural administration of colchicine did not reduce PCI-related myocardial injury or MACE compared with placebo, but attenuation of the inflammatory response was observed in the COLCHICINE-PCI trial, which was presented at the American Heart Association Scientific Sessions.